Last reviewed · How we verify
NCT04800718
Increasing Vision Center Service Utilization
NA trial testing Intervention Arm in Eye Diseases in 1,500 participants. Completed in 30 December 2021.
30 November 2021
Quick facts
| Lead sponsor | Seva Foundation |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 1,500 |
| Start date | 22 February 2021 |
| Primary completion | 30 November 2021 |
| Estimated completion | 30 December 2021 |
| Sites | 1 location across India |
Drugs / interventions tested
- Intervention Arm
Conditions studied
- Eye Diseases — all drugs for Eye Diseases →
Sponsor
Seva Foundation
Who can join
Eligibility, any sex, with Eye Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Vision Centre (primary eyecare facility): a major eye care service model catering to underserved rural areas. The sustainability of rural Vision Centres (VC) in north India is a major challenge due to the under-utilization of services by the local community and stakeholders. This affects self-sustainability and limits the expansion of services in rural areas. Dr. Shroff's Charity Eye Hospital is planning an intervention: door-to-door screening in VC's vicinity areas, to connect with the community. In this operational research, the investigators plan to study if this intervention package, consisting of door-to-door screening and awareness generation in the service area can increase the utilization of VC services to a minimum of 14 out-patient cases per day within the study period and also analyze its cost-effectiveness for scalability. Methodology: The study is a randomized experimental intervention, consisting of 2 VCs (intervention arm and control arm) selected from poor low-performing VCs i.e. walk-in out-patient cases≤ 10 per day, in two operational regions (Vrindavan, Mathura District, and Mohammadi, Kheri District) of Uttar Pradesh. Intervention includes door-to-door screening and awareness generation in 8-12 villages surrounding the VC. The control VC will follow existing practices of awareness generation through community activities and health talks. Data collected from each VC for the 4 months of intervention will include, a number of walk-in patients, spectacles advised, and their uptake, referral, and uptake for cataract and specialty surgery as well as operational expenses. Differences across arms in terms of the number of walk-in patients, referrals, uptake of services, and costs involved would be analyzed. Conclusion: Through this study, the investigators would analyze if our intervention package is effective in increasing the VC service utilization and thus, overall sustainability. The investigators would also study the cost-effectiveness of this intervention, to assess its scalability.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of Door-to-Door Screening and Awareness Generation Activities in the Catchment Areas of Vision Centers on Service Use: Protocol for a Randomized Experimental Study.
Sabherwal S, Chinnakaran A, Sood I, Garg GK, et al · · 2021 · cited 5× · PMID 34734839 · DOI 10.2196/31951
Verify or expand the search:
- PubMed search for NCT04800718
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intervention Arm
Trials testing the same drug.
- NCT07230795 — AI-informed Colorectal Cancer (CRC) Screening Navigation vs. Standard of Care Among Screening-naive Penn Medicine Patien · NA · enrolling by invitation
- NCT06831929 — HPV Ends Here: Increasing Uptake of the HPV Vaccine · NA · recruiting
- NCT05389189 — A Tailored Psychological Intervention (MITIG.RA) for Managing Fatigue in Rheumatoid Arthritis · NA · unknown
- NCT04866810 — The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN) · NA · suspended
- NCT04656353 — An Impact Assessment of a Culturally Tailored Online Psychosocial Program for Chinese Immigrant Women With Breast Cancer · NA · completed
Other recruiting trials for Eye Diseases
Currently open trials in the same condition.
- NCT07322302 — RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs) · NA · recruiting
- NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
- NCT07266948 — Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work · Phase 4 · recruiting
- NCT06812845 — Patterns of Eye Diseases Among Patients Attending The Eye Investigation Unit of Sohag University Hospital · recruiting
- NCT06601101 — Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus · Phase 3 · recruiting
Other Seva Foundation trials
Trials by the same sponsor.
- NCT04834648 — Improve Timely Referral Flow and Compliance of Diabetic Retinopathy Patients · NA · completed
- NCT04829084 — Augmenting Referral Pathway to Improve Uptake of Retinal Services by Diabetic Patients · NA · completed
- NCT04837534 — Improving the Follow up Rate for Pediatric Patients · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04800718 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seva Foundation
- Last refreshed: 10 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04800718.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing